{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"91"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"Percentage of Participants Completing Hematopoietic Stem Cell Transplant (HSCT).","groups":[{"description":"3 cycles of standard of care (SOC) salvage therapy (R-DHAP, R-ICE and R-GDP) per physician's choice. Participants responding to SOC are expected to undergo high dose chemotherapy (HDCT) and hematopoietic stem cell transplant (HSCT). If requested by the investigator, participants may be allowed to receive JCAR017 upon meeting progression, relapse, or suboptimal response. 1 cycle = 3 weeks","id":"OG000","title":"Standard of Care Arm"},{"description":"\\[Lymphodepleting chemotherapy (LDC)\\] Fludarabine IV (30 mg/m\\^2/day for 3 days) and cyclophosphamide IV (300 mg/m\\^2/day for 3 days) followed by JCAR017 IV infusion at a dose of 100 x 10\\^6 JCAR017-positive viable transduced T cells (CAR+ T cells) on Day 29 (2 to 7 days after completion of LD chemotherapy)","id":"OG001","title":"Liso-cel Arm"}],"paramType":"NUMBER","populationDescription":"All treated participants in SOC arm","reportingStatus":"POSTED","timeFrame":"Up to 5 months after first dose","title":"Percentage of Participants Completing Hematopoietic Stem Cell Transplant (HSCT)","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}